Raymond James & Associates Sorrento Therapeutics, Inc. Transaction History

Raymond James & Associates

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.74 - $1.83 $25,382 - $62,769	-34,300 Reduced 13.33%	223,019 $198,000
Q3 2022 Oct 25, 2022	BUY	$1.51 - $2.88 $153,265 - $292,320	101,500 Added 65.14%	257,319 $404,000
Q2 2022 Aug 12, 2022	SELL	$1.24 - $2.33 $13,647 - $25,643	-11,006 Reduced 6.6%	155,819 $313,000
Q1 2022 May 11, 2022	SELL	$2.0 - $4.9 $25,864 - $63,366	-12,932 Reduced 7.19%	166,825 $389,000
Q4 2021 Feb 08, 2022	BUY	$4.65 - $7.23 $130,200 - $202,440	28,000 Added 18.45%	179,757 $836,000
Q3 2021 Nov 02, 2021	BUY	$7.41 - $10.99 $291,213 - $431,907	39,300 Added 34.95%	151,757 $1.16 Million
Q2 2021 Aug 11, 2021	BUY	$6.35 - $10.0 $166,281 - $261,860	26,186 Added 30.35%	112,457 $1.09 Million
Q1 2021 May 14, 2021	SELL	$7.03 - $16.51 $164,248 - $385,739	-23,364 Reduced 21.31%	86,271 $713,000
Q4 2020 Feb 12, 2021	SELL	$5.76 - $11.95 $47,145 - $97,810	-8,185 Reduced 6.95%	109,635 $748,000
Q3 2020 Nov 04, 2020	SELL	$6.17 - $18.82 $703,435 - $2.15 Million	-114,009 Reduced 49.18%	117,820 $1.31 Million
Q2 2020 Jul 28, 2020	BUY	$1.73 - $6.76 $381,601 - $1.49 Million	220,579 Added 1960.7%	231,829 $1.46 Million
Q1 2020 Apr 21, 2020	BUY	$1.57 - $4.76 $17,662 - $53,550	11,250 New	11,250 $21,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.